INTERNATIONAL PATENT: ASTRAZENECA AB FILES APPLICATION FOR "COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS"

GENEVA, April 18 -- ASTRAZENECA AB (SE-151 85 Sodertalje) filed a patent application (PCT/EP2025/078982) for "COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS" on Oct 08, 2025. With publication no. WO/2026/078068, the details related to the patent application was published on Apr 16, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): AMBERY, Philip (c/o AstraZeneca ABSE-151 85 Sodertalje)

Abstract: Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin ar...